A single primary endpoint focused on sexual desire, one pivotal Phase 3 study, and a dose-ranging design the FDA considers reasonable: Arletta Pharma Solutions emerged from a Type C written response with more runway cleared than most clinical-stage companies get before Phase 2 enrollment even opens. The interaction, centered on Lybrido’s MONARCH study (FPS203), matters not just for Arletta but because it lands at a specific regulatory inflection point. The FDA recently formalized a single-trial pathway as its default standard for new drug approvals, pairing one well-controlled pivotal study with confirmatory evidence. Arletta’s program is now explicitly structured around that framework, which reduces both capital exposure and development time without requiring a waiver or a special accommodation.
The clinical logic behind Lybrido is worth holding carefully. The tablet combines a testosterone sublingual coating with an inner sildenafil core, engineered so peak sildenafil plasma concentration coincides with the window of elevated sexual motivation the testosterone produces. It is on-demand, not daily, and targets both psychological and physiological dimensions of FSIAD and HSDD simultaneously. That dual-action mechanism distinguishes it from the two FDA-approved options already in the market: flibanserin (Addyi), approved in 2015 for premenopausal women with HSDD, which acts centrally as a serotonin receptor agonist and dopamine agonist taken daily, and bremelanotide (Vyleesi), a melanocortin receptor agonist administered by injection. A fixed-dose dual-release oral tablet used on demand occupies a different pharmacological and practical position than either of those. The FDA’s endorsement of a single sexual desire endpoint as the primary measure also signals alignment on what the agency considers the core therapeutic target in this population.
The refinements the FDA requested, covering study design, statistical methodology, and safety characterization, are the standard friction of any pre-Phase 2 dialogue and Arletta characterizes them as expected. More consequential is the agency’s noted openness to testosterone-based therapies in women, a posture shift that directly supports Lybrido’s testosterone-containing formulation at a time when off-label testosterone use for female sexual dysfunction has long outpaced regulatory clarity. Arletta also reported positive Phase 2 Clitoral Doppler Duplex Ultrasound results recently, giving the program an objective hemodynamic signal alongside subjective desire data. The company has accumulated results from 20 Phase 1 and Phase 2a trials plus large-scale Phase 2b work across 17 US sites, so the MONARCH study enters an unusually well-characterized safety and dosing context.
The single number to track from here is the primary endpoint responder rate in MONARCH’s dose-ranging arms. FDA has accepted a sexual desire-focused primary endpoint, which means that metric will determine whether the single pivotal Phase 3 pathway remains viable. A weak desire signal in MONARCH forces a redesign; a clean one locks in the most efficient route to an NDA Arletta could realistically have.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
